Day 5 of Loss Streak for Coherus Biosciences Stock with -56% Return (vs. -80% YTD) [11/13/2023] |

Quote
























2.30/share. Looks like investor perception of Denny's all or nothing gamble to bolster our portfolio with Surface is the dead cat we thought it'd be, but without the bounce.
 












anonymous said:
Just give cimerli a little more time, I got a feeling
Click to expand...
Feeling? It must be a stroke coming on. As was stated in another thread, Udenyca took over 33% of the Neulasta market, the highest hospital/onc pharmacy expenditure due to its sheer volume, and our stock barely crested $20/share. That was a much bigger market than eye, and you think Cimerli is going to even make a dent? You should see a doctor asap.
 












Top Bottom
Back
Quote